Last edition
News about "Julian Beach"
Jascayd (Nerandomilast) Wins UK MHRA Approval for Pulmonary Fibrosis Treatment
Nerandomilast (Jascayd) has been approved for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), expanding treatment options for these chronic lung diseases.
Julian Beach | 09/07/2026 | By News Bureau
UK MHRA Approves Retifanlimab for Merkel Cell Skin Cancer
The UK MHRA has approved retifanlimab (ZYNYZ) for the treatment of advanced Merkel Cell Carcinoma (MCC), a rare and aggressive skin cancer with significant unmet medical need.
Julian Beach | 08/07/2026 | By Akanki
Regulators Warn against Promotion of Newly Licensed Weight-Loss Medicines
MHRA, ASA, and GPhC have warned businesses against promoting newly licensed prescription-only and unlicensed weight-loss medicines, reinforcing compliance with advertising regulations and public health protections.
Julian Beach | 20/06/2026 | By News Bureau
UK MHRA Approves Vyjuvek for Treatment of Dystrophic Epidermolysis Bullosa Wounds
Medicines and Healthcare products Regulatory Agency has approved Vyjuvek for treating wounds in patients with dystrophic epidermolysis bullosa, including newborns.
Julian Beach | 18/05/2026 | By News Bureau
MHRA Approves Olezarsen (Tryngolza) for Familial Chylomicronemia Syndrome
MHRA approves olezarsen (tryngolza) for adults with Familial Chylomicronemia Syndrome with subcutaneous injection administration.
Julian Beach | 13/04/2026 | By News Bureau | 100
MHRA Approves Bayer's Sevabertinib for HER2-Mutated Advanced Lung Cancer
Sevabertinib, a targeted therapy for HER2-mutated lung cancer, has been approved by the UK regulator to expand treatment options for advanced-stage patients.
Julian Beach | 04/04/2026 | By News Bureau | 149
MHRA Clears Deuruxolitinib (Leqselvi) by Sun Pharma for Severe Alopecia Areata in Adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) for treating severe Alopecia Areata in adults, granting authorisation to Sun Pharma UK via the International Recognition Procedure (IRP).
Julian Beach | 13/03/2026 | By News Bureau | 123
The UK regulator has approved Inluriyo (imlunestrant tosylate) for adults with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations after prior hormone therapy failure.
Julian Beach | 26/02/2026 | By News Bureau | 181
MHRA Approves Brensocatib as First Targeted Treatment for Non-Cystic Fibrosis Bronchiectasis in UK
UK regulator grants marketing authorisation to brensocatib (Brinsupri) for patients aged 12 and above with recurrent non-cystic fibrosis bronchiectasis flare-ups.
Julian Beach | 24/02/2026 | By News Bureau | 483
MHRA Approves New mRNA COVID-19 Booster
The new approved vaccine, Zapomeran (Kostaive) is cleared for adults aged 18 years and above.
Julian Beach | 05/01/2026 | By News Bureau | 281
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy